Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

No teen herd immunity for 4CMenB in landmark trial

Key clinical point: Meningococcal serogroup B vaccine programs should provide direct protection for those at highest risk.

Major finding: The rate of acquisition of carriage of disease-causing genogroups of Neisseria meningitidis in adolescents 12 months post vaccination with 4CMenB was identical to that in unvaccinated controls.

Study details: This prospective, cluster-randomized trial included nearly 35,000 high school students in the state of South Australia.

Disclosures: The presenter reported receiving research funding from GlaxoSmithKline, the major study sponsor.

Citation:

REPORTING FROM ESPID 2019